Half-Life (Normalesrd) Hours
3-5/4
Plasma Protein Binding %
98-99
Volume Of Distribution L/Kg
0.4
Dose For Normal Renal Function
600 mg q12h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [B]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [B]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 100%, [D]
References
Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995; 333: 1528-33. [PMID: 7477167] / Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997; 41: 898-905. [PMID: 9145841] / Izzedine H, Launay-Vacher V, Legrand M, Aymard G, Deray G. Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient [Letter]. Nephron. 2001; 87: 186-7. [PMID: 11244316] / Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333: 1534-9. [PMID: 7477168]
Toxicity Notes
Many drug interactions.